Background. Fecal microbiota transplantation (FMT), a safe, effective alternative therapy for recurrent Clostridium difficile infection (CDI), is infrequently used, in part because of an assumption that patients are unwilling to consider FMT because of its unappealing nature.
reconstituting the normal intestinal microflora in a diseased person by infusion (via nasogastric tube [NGT] , enema, or colonoscopy) of a liquid suspension of stool from a healthy donor. The first report of the use of FMT (for a patient with non-CDI pseudomembranous colitis) was published in 1958 [16] . Since then, there has been mounting evidence supporting its use in recurrent CDI [11, 12, 15, 17, 18] . A recent systematic review encompassing 317 patients-from 27 case series and reportswith recurrent CDI or pseudomembranous colitis treated with FMT found that 92% of patients showed rapid resolution of infection and symptoms [18] . Its safety profile was excellent [18] .
Despite growing evidence supporting its safety and efficacy, FMT is infrequently used, and is generally considered only as a "last resort" after multiple CDI recurrences and treatment failures. Perhaps the most commonly cited reason for not using FMT is the aesthetics of the treatment. There appears to be a widely held belief that both patients and physicians have an aversion to FMT based on its unappealing nature [4, 11, 12, 15, 17, 19, 20] . However, there are limited published data to support these beliefs. We developed a survey to assess patient perceptions of the aesthetics of FMT and their willingness to consider it as a personal treatment option.
MATERIALS AND METHODS

Survey Development and Validation
We developed a 16-page patient survey with 4 sections: (1) assessment of CDI risk factors and relevant comorbidities, (2) information about treatment and recurrences in respondents who had suffered from CDI, (3) hypothetical scenarios of recurrent CDI with assessment of treatment preference, and (4) demographic data. Focus groups that included members of the hospital's Patient Advisory Group reviewed the survey (which was designed to be at an eighth-grade literacy level) for comprehension before it was administered to study participants.
Respondents were presented with 2 scenarios in which they were asked to imagine they were suffering from an episode of recurrent CDI. In scenario 1, they received a description of common symptoms of CDI along with information about 2 treatment options: (1) another course of antibiotics alone (with a 65% chance of cure) or (2) antibiotics followed by a treatment we called "floral reconstitution" (FR) (with a 90% chance of cure). This terminology was used instead of other more conventional or descriptive terms for FMT to avoid disclosure of what the treatment entailed, as such disclosure was expected to affect the participants' choice. Respondents were asked to select their treatment preference. Those choosing option 1 (antibiotics alone) were asked to indicate the reason for their choice.
In scenario 2, respondents were presented with the same clinical situation and the same treatment options, but were given more detailed information about FR (including the nature of the substance used, possible routes of administration, and information about the safety of the treatment based on the current published literature). They were asked again to select their preferred treatment and, if they chose antibiotics alone, to identify a reason for that choice.
Respondents who selected FR also answered questions about their preferred mode of delivery (enema, colonoscopy, NGT, or other hypothetical options not currently available), their preferred treatment setting (home, physician's office, or hospital), willingness to pay out-of-pocket for treatment, and aspects of FR they considered to be most unappealing, including the need to handle fecal material, the color and odor of the treatment, and the need to discuss the illness and treatment with a donor. Respondents rated a list of unappealing aspects of FR on a 5-point Likert scale, where 1 represented "I don't find this unappealing at all" and 5 represented "This is definitely too unappealing to deal with."
Study Participants and Recruitment
The survey was piloted with a group of outpatient clinic receptionists at our academic medical center in New Hampshire. After completing the survey, they were informed about the study and asked to distribute surveys. During a 1-month period in September 2011, receptionists offered paper surveys to a convenience sample of adult outpatients and accompanying family members when they registered for appointments in a variety of medical and surgical clinics. They collected completed surveys the same day and returned them to investigators in sealed envelopes. Participation was voluntary and anonymous; participants were not compensated.
Ethical Issues
The study protocol was reviewed and exempted by the Dartmouth College Committee for Protection of Human Subjects.
Analysis
We performed simple and stratified analysis of the data, using the latter to evaluate for associations between participant responses and their age, sex, or educational background. In some cases Likert scales were collapsed into 2 categories for analysis: "unappealing enough to interfere with acceptability" (scores 4 and 5) versus "not unappealing enough to interfere with acceptability" (scores 1-3). The McNemar test was used to compare paired proportions and the χ 2 test was used to compare the relationship between categorical variables. P < .05 was considered statistically significant.
RESULTS
A total of 400 surveys were given to clinic receptionists to distribute to clinic patients and their families, and 239 (60%)
were returned, of which 192 were complete and 47 were incomplete or incorrectly completed. One respondent had had an episode of CDI without recurrence and was considered separately from the 191 CDI-naive respondents. Of the 184 respondents who reported demographic information, 129 (70%) were female, 174 (94%) were white, 109 (59%) were aged 50 years or older, and 92 (50%) had graduated from college ( Table 1 ). The majority of respondents (92%) had heard about FR for the first time through our survey. When presented with a hypothetical case of recurrent CDI in scenario 1 (which did not explicitly disclose the fecal nature of FR), 162 of the 191 participants (85%) chose antibiotics followed by FR, and 29 (15%) chose antibiotics alone. Of the 29 respondents who chose antibiotics alone, 15 (52%) believed that another course of antibiotics should be sufficient treatment and 14 (48%) felt that they did not have sufficient information about FR to consider it as a treatment.
After reading scenario 2, which disclosed the fecal nature of FR, 16 respondents changed their choice from antibiotics and FR to antibiotics alone, and 8 respondents changed their choice from antibiotics alone to antibiotics and FR. The total number who chose antibiotics followed by FR (154 or 81%) was not significantly different from scenario 1 (P = .15) ( Table 2 ). Among the 37 respondents who initially chose the treatment option of antibiotics alone after reading scenario 2, 19 (51%) cited concerns about safety and 16 (43%) stated that FR seemed "too gross" ( Table 3 ). The total number of respondents who chose FR in scenario 2 increased to 179 (94%, P < .001) if their physician recommended FR. There was a statistically significant difference between the proportion of patients willing to consider FR as currently formulated (described in scenario 2) and those willing to consider FR if available as a colorless, odorless pill (81% vs 90%, P = .002).
Men and women were equally likely to select a treatment option that included FR. Women who did not select FR were somewhat more likely to cite concerns about the treatment being "too gross to consider" (14% after scenario 1, and 21% after scenario 2), and men were more likely to cite safety concerns. There was no statistically significant difference between different age groups or educational levels and willingness to select FR as a treatment option. Using the 5-point Likert scale, respondents rated all aspects of FR as at least somewhat unappealing (mean rating of ≥2), with the most negative scores associated with the need to handle stool (3.99/5.0) and receiving FR by NGT (4.10/5.0). The least unappealing aspect of the treatment process was the need to discuss the illness and FR with a potential stool donor (2.51/5.0). Only 2 aspects of FR were classified as "unappealing enough to interfere with acceptability" by a majority of respondents: the need to handle stool (rated 4 or 5 by 65%), and the administration of FR by NGT (rated 4 or 5 by 74%) ( Table 4) .
When rating the degree to which different routes of administration were more or less appealing, respondents rated FR by enema (3.04/5.0) and colonoscopy (2.95/5.0) more appealing than receiving FR by NGT (4.10/5.0).
Women were more likely than men to rate the odor of the stool (55% vs 27%, P < .001), and having to handle stool themselves (72% vs 41%, P < .001) as "very unappealing" or "too unappealing to deal with" (Table 4 ). Women also found the idea of administration of FR by NGT more unappealing than men (77% vs 63% rated this administration method as very unappealing or too unappealing; P = .05) (Table 4) . Overall, women rated all aspects of the FR procedure more unappealing than did men (Table 4) . When stratified by age group, there were no significant differences in respondents' likelihood to select treatment options that included FR, or in their preferred formulations. Respondents aged ≥65 years were significantly less likely than younger respondents to rate the need to handle stool (45% vs 72%, P = .002), the odor of the stool (29% vs 54%, P = .004), and the brown color of the formulation (28% vs 49%, P = .017) as "very unappealing" or "too unappealing to deal with" (Table 4) .
Of the 182 respondents willing to consider FR therapy and indicating a preferred treatment venue, 88 (48%) preferred a hospital setting, 71 (39%) a physician's office, and 23 (13%) their own home. Of the 191 total respondents, 147 (77%) indicated a willingness to pay out-of-pocket to receive FR. Of these 147 respondents, 89 (61%) were willing to pay up to $100 and 9 (6%) were willing to pay more than $500. Of the 50 respondents aged ≥65 years, 12 (24%) indicated a willingness to pay more than $500 out of pocket to receive FR compared with 6 (4%) of the 136 respondents <65 years old (P < .001).
The single respondent who reported a prior episode of CDI had been treated with 1 course of oral metronidazole and had not experienced a recurrence. In response to scenarios 1 and 2, this respondent selected the treatment option of antibiotics alone, citing a belief that antibiotics alone should be enough to treat recurrent CDI.
DISCUSSION
Fecal microbiota transplantation has demonstrated notable safety and efficacy as a therapy for recurrent CDI, yet its use has been limited in current medical practice [18] . Reluctance to use FMT has been attributed in part to the unappealing aesthetics of this treatment, and an assumption that patients would be unwilling to consider it [4, 11, 12, 15, 17, 19, 20] . To our knowledge, this is the first study devoted to specifically exploring attitudes toward FMT in patients initially offered FMT as potential treatment for recurrent CDI. Our findings confirm the widely held belief that patients find aspects of FMT "unappealing." Nonetheless, we found that a majority of our patients (up to 94%) would choose to receive FMT along with antibiotics for treatment of recurrent CDI. Our data suggest that patients may be more ready and willing to accept FMT as a treatment alternative for CDI than previously assumed.
Our finding that patients appear open to considering FMT as a treatment alternative, while acknowledging its inherently unappealing nature, supports the findings of Kahn et al [19] . These investigators explored the attitudes of 15 adult patients Data were stratified by male and female responses and by age ≥65 and <65. The χ 2 test was used to compare values between the males and females, and between ages ≥65 and <65.
Abbreviations: FMT, fecal microbiota transplantation; FR, floral restoration; NGT, nasogastric tube. a 1 = not unappealing at all; 3 = very unappealing, but I could probably deal with it; 5 = too unappealing to deal with. b P < .05 was considered statistically significant. and 7 parents of children with ulcerative colitis toward the use of FMT as an adjunctive therapy. A majority expressed interest in FMT and were eager for it to become available for clinical use; many participants reported that living with ulcerative colitis was far worse than the thought of undergoing FMT [19] . In the face of prolonged suffering, significant morbidity, and potential mortality from a chronic, debilitating condition such as ulcerative colitis, it is not surprising that patients regard the "gross factor" of FMT as a small price to pay for a potentially effective treatment. For the respondents in our survey, patients appeared to make a similar judgment when weighing a hypothetical risk of suffering from recurrent CDI against the potential risks and benefits, along with the aesthetics of FMT. Although no prior reports have assessed attitudes toward FMT in FMT-naive patients with recurrent CDI, a report by Brandt et al surveyed the perceptions of 77 patients who had experienced recurrences of CDI and were eventually treated with FMT; 97% noted that they would want FMT in the event of another recurrence, and 53% of them would have opted for FMT as primary treatment prior to a trial of antibiotics for their first recurrence if given the option [21] . These studies suggest that patient education and engagement in a shared decision-making process may play an important role in expanding the adoption of FMT. Moreover, the role of the physician as advisor and source of information may be important. In our study, the hypothetical recommendation of FR by a physician significantly increased the already high acceptance rate of this treatment.
Our findings also suggest an opportunity to expand the clinical use of FMT through developing more aesthetically acceptable protocols. Patients rated all aspects of the FMT procedure at least "somewhat unappealing." We believe that the preference for FMT administration directly into the colon (even by means of colonoscopy!) over the NGT route reflects a particular aversion to the concept of ingesting fecal material. Although not currently available, FMT in the form of a colorless, odorless pill appealed to the greatest number of patients.
While the majority of patients we surveyed were willing to consider trying FMT, in spite of the aesthetics, other concerns were also cited by those who opted not to consider this treatment. In fact, a larger proportion of respondents who did not select FMT as a treatment option reported concerns about the safety of the process. Although no randomized controlled trial safety data are currently available, no significant adverse events attributable to the procedure itself have been reported in case series [18] .
Potential barriers to the use of FMT may have greater influence on physicians than on patients. Until the recent publication by the Fecal Microbiota Working Group of an FMT protocol, there has been no consensus practice guideline for clinicians to use [22] . There is no defined coding or reimbursement pathway for physicians who wish to perform FMT. Thus, while patients seem willing to try FMT, it is unknown how willing physicians are to offer, perform, or refer patients for this treatment, given the possible barriers. To help answer this question, we are currently conducting a tandem survey study to examine physician attitudes toward the use of FMT.
Although it provides the first systematically collected information on patient attitudes about FMT, our study is limited in size and scope and may not be generalizable to all patient populations. We surveyed a convenience sample of patients who received care in ambulatory clinics at our academic medical center in rural New Hampshire. The respondents who completed surveys included a higher proportion of females (70%) and had received more formal education than national averages (68% of participants had pursued some form of postsecondary education) [23] . The group surveyed was essentially CDI-naive, and thus does not provide the perspective of those who have suffered recurrent episodes of CDI. We believe such a group, such as Kahn et al's ulcerative colitis patients, would be even more likely to try FMT, but this hypothesis requires further study.
In this initial study examining patient attitudes toward the use of FMT for the treatment of recurrent CDI, we confirmed the widely held belief that patients find this treatment to have many unappealing aspects. More important, though, we demonstrated that the majority of patients do not find these aspects too unappealing to limit acceptability, and in fact would prefer FMT to repeated courses of antibiotics alone. This finding, if generalizable, suggests a strong rationale for development of shared decision-making tools that include education about the efficacy, safety, and side effect profile of FMT so that patients who suffer from recurrent CDI can make informed choices. Further study is needed to understand and mitigate barriers to acceptability of FMT among physicians. Finally, the preference for FMT formulations that are more aesthetically pleasing, such as tablets or capsules, would both eliminate a potential barrier to treatment for some patients and reduce the necessity for technological healthcare resources and procedure time for clinicians. In the meantime, physicians caring for patients who have recurrent CDI should push past the aesthetics of FMT to engage their patients in an informed discussion about this treatment option. The evidence suggests that such a discussion may be well received and appreciated by many patients.
Notes
